Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice
暂无分享,去创建一个
Laura Conti | Federica Cavallo | Stefania Lanzardo | S. Lanzardo | L. Conti | F. Cavallo | Roberto Ruiu | Giuseppina Barutello | Marco Macagno | Silvio Bandini | Marco Macagno | R. Ruiu | G. Barutello | Silvio Bandini | Roberto Ruiu
[1] Xia Zhao,et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. , 2006, Carcinogenesis.
[2] A. Levchenko,et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. , 2012, The Journal of clinical investigation.
[3] G. Goodall,et al. microRNAs and EMT in Mammary Cells and Breast Cancer , 2010, Journal of Mammary Gland Biology and Neoplasia.
[4] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] Federica Cavallo,et al. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. , 2008, Neoplasia.
[6] G. Forni,et al. Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike? , 2008, Cancer Immunology, Immunotherapy.
[7] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[8] E. Raymond,et al. Resistance to human epidermal growth factor receptor type 2-targeted therapies. , 2014, European journal of cancer.
[9] Jorge R. Oksenberg,et al. The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease , 2001, Science.
[10] Kelly K. Haagenson,et al. Mitogen activated protein kinase phosphatases and cancer , 2010, Cancer biology & therapy.
[11] M. Lai,et al. A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA , 2009, Clinical Cancer Research.
[12] G. Weber,et al. Osteopontin‐c is a selective marker of breast cancer , 2008, International journal of cancer.
[13] L. Rhodes,et al. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk , 2010, Molecular Cancer.
[14] F. Orso,et al. miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. , 2013, The American journal of pathology.
[15] Yuan Yuan Wang,et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. , 2011, Cancer research.
[16] M. Manns,et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.
[17] G. Forni,et al. Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice1 , 2006, The Journal of Immunology.
[18] S. Colowick,et al. Methods in Enzymology , Vol , 1966 .
[19] A. Harris,et al. Mechanisms of resistance to antiangiogenesis therapy. , 2010, European journal of cancer.
[20] P. Musiani,et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway , 2009, Journal of cellular and molecular medicine.
[21] S. Segal,et al. CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.
[22] H. Boehmer,et al. Mechanisms of suppression by suppressor T cells , 2005, Nature Immunology.
[23] Rosanna La Rocca,et al. Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.
[24] R. Christensen,et al. Mesenchymal stem cells, cancer challenges and new directions. , 2014, European journal of cancer.
[25] Xiaoqiang Tang. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. , 2013, Cancer letters.
[26] M. Colombo,et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. , 1996, Cancer Research.
[27] D. White,et al. Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner. , 2013, Cell reports.
[28] D. Amadori,et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis , 2013, Nature Cell Biology.
[29] G. Solgi,et al. Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material , 2011, European journal of immunology.
[30] R. Kaaks,et al. Obesity and breast cancer , 2019, Oncolog-Hematolog.ro.
[31] Xueying Sun,et al. The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival , 2011, Clinical & developmental immunology.
[32] I. Fentiman,et al. Inflammation and breast cancer , 2013 .
[33] Sha Huang,et al. Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-β. , 2012, International journal of oncology.
[34] Suhas D. Doke,et al. Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers , 2013, Oncology letters.
[35] G. Forni,et al. Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice , 2007, Breast Cancer Research.
[36] G. Forni,et al. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αv β3 integrins. , 2013, Contrast media & molecular imaging.
[37] G. Dubyak,et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. , 2008, Immunity.
[38] Kunwei Shen,et al. Stromal cells in tumor microenvironment and breast cancer , 2012, Cancer and Metastasis Reviews.
[39] N. Maitland,et al. Cancer stem cells, models of study and implications of therapy resistance mechanisms. , 2011, Advances in experimental medicine and biology.
[40] M. Bianchi,et al. High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity , 2007, Immunological reviews.
[41] P. Scherer. From Lipid Storage Compartment to Endocrine Organ , 2006 .
[42] A. Roberts,et al. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β , 2005, Journal of Cell Science.
[43] M. Soares,et al. Identification of MicroRNAs as Potential Prognostic Markers in Ependymoma , 2011, PloS one.
[44] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[45] Frank P Barry,et al. Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.
[46] R. Clarke,et al. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells , 2013, Breast Cancer Research.
[47] Hui Zhou,et al. Novel Mechanism of Anti-apoptotic Function of 78-kDa Glucose-regulated Protein (GRP78) , 2011, The Journal of Biological Chemistry.
[48] M. Matúšková,et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. , 2007, Cancer research.
[49] N. Normanno,et al. Mesenchymal stem cell‐derived interleukin‐6 and vascular endothelial growth factor promote breast cancer cell migration , 2012, Journal of cellular biochemistry.
[50] R. Hovey,et al. Diverse and Active Roles for Adipocytes During Mammary Gland Growth and Function , 2010, Journal of Mammary Gland Biology and Neoplasia.
[51] F. Caldefie‐Chézet,et al. Molecular mechanisms of leptin and adiponectin in breast cancer. , 2011, European journal of cancer.
[52] Bao-feng Zhang,et al. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis , 2010, Journal of digestive diseases.
[53] Valentin Djonov,et al. Angiogenesis in cancer - general pathways and their therapeutic implications. , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[54] S. Lens,et al. The Aurora kinase family in cell division and cancer. , 2008, Biochimica et biophysica acta.
[55] E. Shevach,et al. Absent C3a and C5a receptor signaling into CD4+ T cells enables auto-inductive TGF-β1 signaling and induction of Foxp3+ T regulatory cells , 2012, Nature Immunology.
[56] Piero Musiani,et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. , 2004, The Journal of clinical investigation.
[57] F. Garrido,et al. MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.
[58] K. Mohammad,et al. Role of TGF-β in breast cancer bone metastases , 2013, Advances in bioscience and biotechnology.
[59] Andrew R. Chin,et al. Cytokines driving breast cancer stemness , 2014, Molecular and Cellular Endocrinology.
[60] P. Scherer. Adipose Tissue , 2006, Diabetes.
[61] N. Gobran,et al. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. , 2006, The Egyptian journal of immunology.
[62] M. Andersson,et al. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. , 2009, Cancer treatment reviews.
[63] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[64] Philippe Valet,et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. , 2012, Cancer letters.
[65] Peter Olson,et al. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.
[66] Jack C. Yu,et al. Breast Cancer Cell-Derived Fibroblast Growth Factor 2 and Vascular Endothelial Growth Factor Are Chemoattractants for Bone Marrow Stromal Stem Cells , 2008, Annals of surgery.
[67] B. Herman,et al. Transactivation of erbB2 by short and long isoforms of leptin receptors , 2004, FEBS letters.
[68] P. Musiani,et al. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice , 2013, Oncoimmunology.
[69] Juntian Liu,et al. Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer , 2013, The Journal of Immunology.
[70] Yao‐Hua Song,et al. Epithelial–mesenchymal transition in breast cancer lines is mediated through PDGF‐D released by tissue‐resident stem cells , 2012, International journal of cancer.
[71] P. Musiani,et al. DNA vaccination against membrane-bound Kit ligand: a new approach to inhibiting tumour growth and angiogenesis. , 2014, European journal of cancer.
[72] Steven J. Greco,et al. Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-β , 2010, The Journal of Immunology.
[73] D. Prockop. Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues , 1997, Science.
[74] M. Pevsner-Fischer,et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. , 2007, Blood.
[75] P. Lollini,et al. Oncoantigens for an immune prevention of cancer. , 2011, American journal of cancer research.
[76] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[77] Y. Ko,et al. Phthalates stimulate the epithelial to mesenchymal transition through an HDAC6-dependent mechanism in human breast epithelial stem cells. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[78] D. Birnbaum,et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.
[79] Francesca Cordero,et al. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention , 2005, BMC Bioinformatics.
[80] Jay A. Berzofsky,et al. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation , 2008, Cancer Immunology, Immunotherapy.
[81] Federica Cavallo,et al. Are oncoantigens suitable targets for anti-tumour therapy? , 2007, Nature Reviews Cancer.
[82] H. Moses,et al. The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.
[83] E. van Marck,et al. Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival , 2004, Clinical Cancer Research.
[84] M. Dieci,et al. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. , 2010, Cancer treatment reviews.
[85] Max S Wicha,et al. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.
[86] A. Amici,et al. Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients , 2014, Clinical Cancer Research.
[87] J. Volff,et al. Genetic, biochemical and evolutionary facets of Xmrk-induced melanoma formation in the fish Xiphophorus. , 2004, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.
[88] R. Tavares,et al. Claudin Expression in High Grade Invasive Ductal Carcinoma of the Breast: Correlation with the Molecular Subtype , 2012, Modern Pathology.
[89] P. Scherer,et al. Adipose tissue remodeling and obesity. , 2011, The Journal of clinical investigation.
[90] Stefanie Dimmeler,et al. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. , 2008, Cardiovascular research.
[91] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[92] Piero Musiani,et al. Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity , 2005, Clinical Cancer Research.
[93] L. Ellis,et al. Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies , 2008, Cancer journal.
[94] Alberto Mantovani,et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.
[95] Laura Conti,et al. The noninflammatory role of high mobility group box 1/toll‐like receptor 2 axis in the self‐renewal of mammary cancer stem cells , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[96] G. Dontu,et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. , 2011, Cancer research.
[97] Jeong-Seok Nam,et al. TNFα-exposed Bone Marrow-derived Mesenchymal Stem Cells Promote Locomotion of MDA-MB-231 Breast Cancer Cells through Transcriptional Activation of CXCR3 Ligand Chemokines* , 2010, The Journal of Biological Chemistry.
[98] Federica Cavallo,et al. 2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.
[99] M. Colombo,et al. immune reactivity mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses Myeloid cell expansion elicited by the progression of spontaneous , 2013 .
[100] U. Vaishampayan. Cabozantinib as a Novel Therapy for Renal Cell Carcinoma , 2013, Current Oncology Reports.
[101] Jacqueline Capeau,et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. , 2006, European cytokine network.
[102] T. Misteli,et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.
[103] John P A Ioannidis,et al. Clinical outcome prediction by microRNAs in human cancer: a systematic review. , 2012, Journal of the National Cancer Institute.
[104] M. Sliwkowski,et al. Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy , 2013, Clinical Cancer Research.
[105] P. Lollini,et al. Preclinical vaccines against mammary carcinoma , 2013, Expert review of vaccines.
[106] Kristian Pietras,et al. Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.
[107] L. Lashinger,et al. Decreased systemic IGF‐1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor‐κB activation, and inflammation‐related gene expression , 2013, Molecular carcinogenesis.
[108] Erwin G. Van Meir,et al. Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. , 2002, Gene.
[109] B. Elliott,et al. Capacity of adipose tissue to promote growth and metastasis of a murine mammary carcinoma: Effect of estrogen and progesterone , 1992, International journal of cancer.
[110] R. Irby,et al. Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression , 2005, Molecular carcinogenesis.
[111] L. Holmgren,et al. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. , 2001, The Journal of cell biology.
[112] J. Medema,et al. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? , 2013, Cancer letters.
[113] Federica Cavallo,et al. Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies , 2010, The Journal of Immunology.
[114] M. Kerin,et al. Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells , 2007, Clinical Cancer Research.
[115] Marnie L. Gruen,et al. Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. , 2007, American journal of physiology. Cell physiology.
[116] L. Holmgren,et al. Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells. , 2008, Biochimica et biophysica acta.
[117] F. Jin,et al. Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer , 2011, Journal of Investigative Medicine.
[118] Ying Lu,et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. , 2007, Magnetic resonance imaging.
[119] K. Glaser,et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.
[120] C. Lynch,et al. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. , 2011, Cancer letters.
[121] M. VanSaun. Molecular Pathways Molecular Pathways : Adiponectin and Leptin Signaling in Cancer , 2013 .
[122] Ross Tubo,et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.
[123] David A. Peterson,et al. AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition , 2013, Molecular Cancer Research.
[124] Y. Rui,et al. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors , 2013, Stem Cell Research & Therapy.
[125] Jeffrey W Pollard,et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.
[126] Michelle Collazo,et al. Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.
[127] K. Odunsi,et al. PGE2-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells , 2012, Immunological investigations.
[128] G. Watkins,et al. Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer , 2006, BMC Cancer.
[129] P. Musiani,et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. , 2006, Cancer research.
[130] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[131] E. Mayer,et al. Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies , 2010, Clinical Cancer Research.
[132] W. Ye,et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. , 2012, Cancer research.
[133] M. Wicha,et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.
[134] A. Xiang,et al. Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. , 2011, Cellular immunology.
[135] Irmeli Barkefors,et al. A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors , 2012, Angiogenesis.
[136] J. Hassell,et al. Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. , 2010, Cancer research.
[137] C. Dray,et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. , 2013, Cancer research.
[138] Mahitosh Mandal,et al. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling , 2013, BMC Cancer.
[139] M. Andreeff,et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.
[140] S. Wilhelm,et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.
[141] P. Musiani,et al. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. , 2005, Vaccine.
[142] S. Dave,et al. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. , 2011, Cancer research.
[143] D. Banerjee,et al. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. , 2010, Experimental cell research.
[144] Peter Dirks,et al. Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.
[145] M. Soares,et al. Identification of Differentially Expressed MicroRNAs in Osteosarcoma , 2011, Sarcoma.
[146] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[147] D. Davies,et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. , 2009, Cancer research.
[148] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[149] M. Andreeff,et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells , 2008, Gene Therapy.
[150] S. H. van der Burg,et al. Vaccination for treatment and prevention of cancer in animal models. , 2006, Advances in immunology.
[151] L. Makowski,et al. The inflammation highway: metabolism accelerates inflammatory traffic in obesity , 2012, Immunological reviews.
[152] P. Musiani,et al. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. , 2001, Cancer research.
[153] Marco Beccuti,et al. Multi-level model for the investigation of oncoantigen-driven vaccination effect , 2013, BMC Bioinformatics.
[154] X. Pei,et al. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway , 2012, Breast Cancer Research and Treatment.
[155] G. Landberg,et al. Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms , 2012, Clinical Cancer Research.
[156] G. Mills,et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. , 2008, Cancer research.
[157] K. Blackwell,et al. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells , 2012, Breast Cancer Research.
[158] P. Musiani,et al. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. , 2008, Current cancer drug targets.
[159] Kshitiz,et al. Erratum: Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis (Journal of Clinical Investigation (2013) 123: 1 (189-205) DOI: 10.1172/JCI64993) , 2013 .
[160] J. Turkson,et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. , 2010, Cancer research.
[161] P. Sinha,et al. Inflammation enhances myeloid‐derived suppressor cell cross‐talk by signaling through Toll‐like receptor 4 , 2009, Journal of leukocyte biology.
[162] A. Amici,et al. Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans , 2011, Cancers.
[163] S. Seok,et al. Cyclooxygenase-2 Inhibition Blocks M2 Macrophage Differentiation and Suppresses Metastasis in Murine Breast Cancer Model , 2013, PloS one.
[164] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[165] M. Colombo,et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.
[166] P. Musiani,et al. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.
[167] H. Fujii,et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression , 2012, Oncoimmunology.
[168] G. Sonpavde,et al. Pazopanib: A novel multitargeted tyrosine kinase inhibitor , 2007, Current oncology reports.
[169] P. Lollini,et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. , 2010, Cancer research.
[170] J. Bromberg. Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.
[171] V. Semiglazov,et al. Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: Role of menopausal status, estrogens and hyperglycemia , 2007, International journal of cancer.
[172] G. Riethmüller,et al. Monoclonal antibodies in cancer therapy , 2004, Springer Seminars in Immunopathology.
[173] C. Arteaga,et al. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. , 2013, Cancer research.
[174] P. Musiani,et al. Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice , 2014, The Journal of Immunology.
[175] D. Carter,et al. Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs , 2012, Clinical Cancer Research.
[176] Piero Musiani,et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.
[177] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[178] B. Vonderhaar,et al. Local regulation of human breast xenograft models , 2010, Journal of cellular physiology.
[179] D. Xie,et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. , 2012, Journal of hepatology.
[180] J. C. Love,et al. In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.
[181] Xin-Yun Huang,et al. Signal Transducers and Activators of Transcription 3 (STAT3) Directly Regulates Cytokine-induced Fascin Expression and Is Required for Breast Cancer Cell Migration* , 2011, The Journal of Biological Chemistry.
[182] Ming O. Li,et al. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells , 2013, The Journal of experimental medicine.
[183] W. Woodward,et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. , 2007, Cancer research.
[184] M. A. Leroux,et al. Concise Review: Role of Mesenchymal Stem Cells in Wound Repair , 2012, Stem cells translational medicine.
[185] P. Musiani,et al. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. , 2007, Cancer research.
[186] P. Dahm,et al. Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma1 , 2008, The Journal of Immunology.
[187] David J Harrison,et al. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. , 2012, Cellular signalling.
[188] Z. Werb,et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.
[189] M. Andreeff,et al. Origins of the Tumor Microenvironment: Quantitative Assessment of Adipose-Derived and Bone Marrow–Derived Stroma , 2012, PloS one.
[190] Ruth S. Waterman,et al. A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype , 2010, PloS one.
[191] B. Rollins,et al. CCL2 (monocyte chemoattractant protein-1) and cancer. , 2004, Seminars in cancer biology.
[192] P. Gaulard,et al. New biomarkers in T-cell lymphomas. , 2012, Best practice & research. Clinical haematology.
[193] M. Campiglio,et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[194] H. Yao,et al. B7-H4 expression in various tumors determined using a novel developed monoclonal antibody , 2011, Clinical and Experimental Medicine.
[195] I. Shimokawa,et al. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. , 2008, American journal of clinical pathology.
[196] G. Pagès,et al. Mechanisms of resistance to anti-angiogenesis therapies. , 2013, Biochimie.
[197] J. Borg,et al. Angiomotin-Like Protein 1 Controls Endothelial Polarity and Junction Stability During Sprouting Angiogenesis , 2009, Circulation research.
[198] R. Weinberg,et al. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. , 2012, Cancer discovery.
[199] M. Frank,et al. The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.
[200] L. Klampfer. The role of signal transducers and activators of transcription in colon cancer. , 2008, Frontiers in bioscience : a journal and virtual library.
[201] D. Doval,et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[202] B. Asselain,et al. Is obesity an independent prognosis factor in woman breast cancer? , 2008, Breast Cancer Research and Treatment.
[203] J. Quiles,et al. Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach. , 2010, Cancer treatment reviews.
[204] W. Gerald,et al. Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.
[205] A. Hakura,et al. Abrogation of c-kit/Steel factor-dependent tumorigenesis by kinase defective mutants of the c-kit receptor: c-kit kinase defective mutants as candidate tools for cancer gene therapy. , 1996, Cancer research.
[206] F. Anania,et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. , 2008, Cancer research.
[207] P. Scherer,et al. Paracrine and endocrine effects of adipose tissue on cancer development and progression. , 2011, Endocrine reviews.
[208] G. Kollias,et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. , 1999, Nature medicine.
[209] E. Li,et al. Prognostic significance of desmoglein 2 and desmoglein 3 in esophageal squamous cell carcinoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[210] B. Groner,et al. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer , 2012, Oncogene.
[211] A. Ryan,et al. ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity , 2005, British Journal of Cancer.
[212] M. Dewhirst,et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.